WallStSmart

Abbott Laboratories (ABT)vsNeuronetics Inc (STIM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 29619% more annual revenue ($44.33B vs $149.16M). ABT leads profitability with a 14.7% profit margin vs -26.2%. ABT earns a higher WallStSmart Score of 51/100 (C-).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

STIM

Hold

38

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued

Intrinsic value data unavailable for STIM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

STIM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
85.7%10/10

Revenue surging 85.7% year-over-year

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

STIM4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$100.45M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-134.9%2/10

ROE of -134.9% — below average capital efficiency

Profit MarginProfitability
-26.2%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : STIM

The strongest argument for STIM centers on Revenue Growth. Revenue growth of 85.7% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : STIM

The primary concerns for STIM are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

ABT profiles as a value stock while STIM is a hypergrowth play — different risk/reward profiles.

STIM carries more volatility with a beta of 0.94 — expect wider price swings.

STIM is growing revenue faster at 85.7% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (51/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Neuronetics Inc

HEALTHCARE · MEDICAL DEVICES · USA

Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.

Want to dig deeper into these stocks?